- Conditions
- Healthy Participants, Obesity
- Interventions
- AZD1043, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumor, Advanced Breast Cancer
- Interventions
- Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Healthy Volunteer, Cystic Fibrosis
- Interventions
- PTI-801, Placebo, PTI-808
- Drug
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma
- Interventions
- AXL1717
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma, Soft Tissue Sarcoma
- Interventions
- LY3039478, Taladegib, Abemaciclib, Cisplatin, Gemcitabine, Carboplatin, LY3023414
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Miami, Florida • Detroit, Michigan • New York, New York + 1 more
- Conditions
- HIV -1 Infection
- Interventions
- BNT351, Placebo
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
- Conditions
- Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
- Interventions
- Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies, Metastases, Oncology, Ovarian Cancer, Solid Tumors, Tumors
- Interventions
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan, B3: AMG 386 15mg/kg + Topotecan
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Sacramento, California • Orlando, Florida + 6 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 9
- States / cities
- Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Breast Cancer, Solid Tumors, Adult
- Interventions
- STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
- Conditions
- Allergic Rhinitis
- Interventions
- CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
- Biological · Other
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 63 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Advanced Solid Tumors
- Interventions
- Dalutrafusp alfa, mFOLFOX6 Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more
- Conditions
- Late-onset Pompe Disease
- Interventions
- DNL952
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Irvine, California • St Louis, Missouri • Durham, North Carolina + 1 more
- Conditions
- Hepatitis C
- Interventions
- telaprevir
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Coronado, California • Los Angeles, California + 22 more
- Conditions
- Malignant Solid Tumor
- Interventions
- Necitumumab, Gemcitabine, Cisplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • Las Vegas, Nevada + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- ITI-1284 10 mg, ITI-1284 20 mg
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Safety Issues, Tolerance
- Interventions
- FC-12738, Saline
- Drug
- Lead sponsor
- Neurodegenerative Disease Research Inc
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Berlin, New Jersey
- Conditions
- Healthy Volunteers
- Interventions
- Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Revumenib, Ruxolitinib, FEDRATINIB, Momelotinib
- Drug
- Lead sponsor
- John Mascarenhas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Delray Beach, Florida + 6 more
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
- Interventions
- TT-00420, Nab-Paclitaxel
- Drug · Combination Product
- Lead sponsor
- TransThera Sciences (Nanjing), Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
- Interventions
- Vigil, Durvalumab
- Biological · Drug
- Lead sponsor
- Mary Crowley Medical Research Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
- Interventions
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Device · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia